Neoplastic meningitis

Article

Abstract

Neoplastic meningitis (NM) occurs in approximately 5% of all patients with cancer. NM is a disease affecting the entire neuraxis, so staging and treatment need to encompass all cerebrospinal fluid (CSF) compartments. Central nervous system staging of NM includes contrast-enhanced brain and spine imaging and radionuclide CSF flow study. Treatment of NM incorporates involved-field radiotherapy of bulky or symptomatic disease sites and intra-CSF drug therapy. The inclusion of concomitant systemic therapy may benefit patients with NM and may obviate the need for intra-CSF chemotherapy. At present, intra-CSF drug therapy is confined to three chemotherapeutic agents (ie, methotrexate, cytosine arabinoside, and thiotepa) administered on a variety of schedules either by intralumbar or intraventricular drug delivery. Although treatment of NM is palliative, with an expected median patient survival of 3 to 6 months, it often affords stabilization and protection from further neurologic deterioration in patients with NM.

References and Recommended Reading

  1. 1.
    Shapiro WR, Posner JB, Ushio Y, et al.: Treatment of meningeal neoplasms. Cancer Treat Rep 1977, 61:733–743.PubMedGoogle Scholar
  2. 2.
    Nugent JL, Bunn PA Jr, Matthews MJ, et al.: CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer 1979, 44:1885–1893.PubMedCrossRefGoogle Scholar
  3. 3.
    Kaplan JG, DeSouza TG, Farkash A, et al.: Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990, 9:225–229.PubMedCrossRefGoogle Scholar
  4. 4.
    Siegal T, Lossos A, Pfeffer MR: Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994, 44:1463–1469.PubMedGoogle Scholar
  5. 5.
    Chamberlain MC: Carcinomatous meningitis. Arch Neurol 1997, 54:16–17.PubMedGoogle Scholar
  6. 6.
    Glass JP, Melamed M, Chernik NL, et al.: Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979, 29:1369–1375.PubMedGoogle Scholar
  7. 7.
    Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982, 49:759–772.PubMedCrossRefGoogle Scholar
  8. 8.
    Little JR, Dale AJ, Okazaki H: Meningeal carcinomatosis. Clinical manifestations. Arch Neurol 1974, 30:138–143.PubMedGoogle Scholar
  9. 9.
    Rosen ST, Aisner J, Makuch RW, et al.: Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore) 1982, 61:45–53.CrossRefGoogle Scholar
  10. 10.
    Amer MH, AlSarraf M, Baker LH, et al.: Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978, 42:660–668.PubMedCrossRefGoogle Scholar
  11. 11.
    Yap HY, Yap BS, Tashima CK, et al.: Meningeal carcinomatosis in breast cancer. Cancer 1978, 42:283–286.PubMedCrossRefGoogle Scholar
  12. 12.
    van Oostenbrugge RJ, Twijnstra A: Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology 1999, 53:382–385.PubMedGoogle Scholar
  13. 13.
    Balm M, Hammack J: Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996, 53:626–632.PubMedGoogle Scholar
  14. 14.
    Sorensen SC, Eagan RT, Scott M: Meningeal carcinomatosis in patients with primary breast or lung cancer. Mayo Clin Proc 1984, 59:91–94.PubMedGoogle Scholar
  15. 15.
    Gonzalez-Vitale JC, Garcia-Bunuel R: Meningeal carcinomatosis. Cancer 1976, 37:2906–2911.PubMedCrossRefGoogle Scholar
  16. 16.
    Grossman SA, Krabak MJ: Leptomeningeal carcinomatosis. Cancer Treat Rev 1999, 25:103–119.PubMedCrossRefGoogle Scholar
  17. 17.
    Chamberlain MC: Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol 1998, 38:135–140.PubMedCrossRefGoogle Scholar
  18. 18.
    Boyle R, Thomas M, Adams JH: Diffuse involvement of the leptomeninges by tumour—a clinical and pathological study of 63 cases. Postgrad Med J 1980, 56:149–158.PubMedGoogle Scholar
  19. 19.
    Wolfgang G, Marcus D, Ulrike S: Leptomeningeal carcinomatosis: clinical syndrome in different primaries. J Neurooncol 1998, 38:103–110.PubMedCrossRefGoogle Scholar
  20. 20.
    Chamberlain MC, Kormanik PR: Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 1997, 35:55–64.PubMedCrossRefGoogle Scholar
  21. 21.
    Kolmel HW: Cytology of neoplastic meningosis. J Neurooncol 1998, 38:121–125.PubMedCrossRefGoogle Scholar
  22. 22.
    Murray JJ, Greco FA, Wolff SN, et al.: Neoplastic meningitis. Marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med 1983, 75:289–294.PubMedCrossRefGoogle Scholar
  23. 23.
    Rogers LR, Duchesneau PM, Nunez C, et al.: Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology 1992, 42:1239–1241.PubMedGoogle Scholar
  24. 24.
    Chamberlain MC, Kormanik PA, Glantz MJ: A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro-oncology 2001, 3:42–45.PubMedGoogle Scholar
  25. 25.
    Glantz MJ, Cole BF, Glantz LK, et al.: Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998, 82:733–739.PubMedCrossRefGoogle Scholar
  26. 26.
    DeAngelis LM: Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998, 38:245–252.PubMedCrossRefGoogle Scholar
  27. 27.
    Wasserstrom WR, Schwartz MK, Fleisher M, et al.: Cerebrospinal fluid biochemical markers in central nervous system tumors: a review. Ann Clin Lab Sci 1981, 11:239–251.PubMedGoogle Scholar
  28. 28.
    Van Zanten AP, Twijnstra A, Hart AA, et al.: Cerebrospinal fluid lactate dehydrogenase activities in patients with central nervous system metastases. Clin Chim Acta 1986, 161:259–268.PubMedCrossRefGoogle Scholar
  29. 29.
    Klee GG, Tallman RD, Goellner JR, et al.: Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis. Mayo Clin Proc 1986, 61:9–13.PubMedGoogle Scholar
  30. 30.
    Twijnstra A, van Zanten AP, Hart AA, et al.: Serial lumbar and ventricle cerebrospinal fluid lactate dehydrogenase activities in patients with leptomeningeal metastases from solid and haematological tumours. J Neurol Neurosurg Psychiatry 1987, 50:313–320.PubMedGoogle Scholar
  31. 31.
    Stockhammer G, Poewe W, Burgstaller S, et al.: Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000, 54:1670–1676.PubMedGoogle Scholar
  32. 32.
    Chamberlain MC: Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology 1998, 50:1173–1175.PubMedGoogle Scholar
  33. 33.
    Garson JA, Coakham HB, Kemshead JT, et al.: The role of monoclonal antibodies in brain tumour diagnosis and cerebrospinal fluid (CSF) cytology. J Neurooncol 1985, 3:165–171.PubMedCrossRefGoogle Scholar
  34. 34.
    Hovestadt A, Henzen-Logmans SC, Vecht CJ: Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis. Br J Cancer 1990, 62:653–654.PubMedGoogle Scholar
  35. 35.
    Boogerd W, Vroom TM, van Heerde P, et al.: CSF cytology versus immunocytochemistry in meningeal carcinomatosis. J Neurol Neurosurg Psychiatry 1988, 51:142–145.PubMedCrossRefGoogle Scholar
  36. 36.
    Van Oostenbrugge RJ, Hopman AH, Ramaekers FC, et al.: In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis. J Neurooncol 1998, 38:127–133.PubMedCrossRefGoogle Scholar
  37. 37.
    Cibas ES, Malkin MG, Posner JB, et al.: Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluid. Am J Clin Pathol 1987, 88:570–577.PubMedGoogle Scholar
  38. 38.
    Biesterfeld S, Bernhard B, Bamborschke S, et al.: DNA single cell cytometry in lymphocytic pleocytosis of the cerebrospinal fluid. Acta Neuropathol (Berl) 1993, 86:428–432.CrossRefGoogle Scholar
  39. 39.
    Van Oostenbrugge RJ, Hopman AH, Arends JW, et al.: The value of interphase cytogenetics in cytology for the diagnosis of leptomeningeal metastases. Neurology 1998, 51:906–908.PubMedGoogle Scholar
  40. 40.
    Rhodes CH, Glantz MJ, Glantz L, et al.: A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 1996, 77:543–548.PubMedCrossRefGoogle Scholar
  41. 41.
    Cheng TM, O’Neill BP, Scheithauer BW, et al.: Chronic meningitis: the role of meningeal or cortical biopsy. Neurosurgery 1994, 34:590–595.PubMedCrossRefGoogle Scholar
  42. 42.
    Chamberlain MC, Sandy AD, Press GA: Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990, 40:435–438.PubMedGoogle Scholar
  43. 43.
    Schumacher M, Orszagh M: Imaging techniques in neoplastic meningiosis. J Neurooncol 1998, 38:111–120.PubMedCrossRefGoogle Scholar
  44. 44.
    Sze G, Soletsky S, Bronen R, et al.: MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. AJR Am J Roentgenol 1989, 153:1039–1049.PubMedGoogle Scholar
  45. 45.
    Schuknecht B, Huber P, Buller B, et al.: Spinal leptomeningeal neoplastic disease. Evaluation by MR, myelography and CT myelography. Eur Neurol 1992, 32:11–16.PubMedCrossRefGoogle Scholar
  46. 46.
    Chamberlain MC: Comparative spine imaging in leptomeningeal metastases. J Neurooncol 1995, 23:233–238.PubMedCrossRefGoogle Scholar
  47. 47.
    Freilich RJ, Krol G, DeAngelis LM: Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995, 38:51–57.PubMedCrossRefGoogle Scholar
  48. 48.
    Mittl RL Jr, Yousem DM: Frequency of unexplained meningeal enhancement in the brain after lumbar puncture. AJNR Am J Neuroradiol 1994, 15:633–638.PubMedGoogle Scholar
  49. 49.
    Glantz MJ, Hall WA, Cole BF, et al.: Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995, 75:2919–2931.PubMedCrossRefGoogle Scholar
  50. 50.
    Grossman SA, Trump CL, Chen DC, et al.: Cerebrospinal flow abnormalities in patients with neoplastic meningitis. Am J Med 1982, 73:641–647.PubMedCrossRefGoogle Scholar
  51. 51.
    Chamberlain MC, Kormanik PA: Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 1996, 46:1674–1677.PubMedGoogle Scholar
  52. 52.
    Mason WP, Yeh SD, DeAngelis LM: 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1998, 50:438–444.PubMedGoogle Scholar
  53. 53.
    Chamberlain MC, Corey-Bloom J: Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology 1991, 41:1765–1769.PubMedGoogle Scholar
  54. 54.
    Chamberlain MC, Kormanik P, Jaeckle KA, et al.: 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1999, 52:216–217.PubMedGoogle Scholar
  55. 55.
    Hildebrand J: Prophylaxis and treatment of leptomeningeal carcinomatosis in solid tumors of adulthood. J Neurooncol 1998, 38:193–198.PubMedCrossRefGoogle Scholar
  56. 56.
    Chamberlain MC, Kormanik PA: Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol 1997, 54:1364–1368.PubMedGoogle Scholar
  57. 57.
    Chamberlain MC: Neoplastic meningitis-related encephalopathy: prognostic significance. Neurology 2003, 60:A17–A18.CrossRefGoogle Scholar
  58. 58.
    Shapiro WR, Young DF, Mehta BM: Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975, 293:161–166.PubMedGoogle Scholar
  59. 59.
    Berweiler U, Krone A, Tonn JC: Reservoir systems for intraventricular chemotherapy. J Neurooncol 1998, 38:141–143.PubMedCrossRefGoogle Scholar
  60. 60.
    Sandberg DI, Bilsky MH, Souweidane MM, et al.: Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 2000, 47:49–54.PubMedCrossRefGoogle Scholar
  61. 61.
    Sause WT, Crowley J, Eyre HJ, et al.: Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases—a Southwest Oncology Group study. J Neurooncol 1988, 6:107–112.PubMedCrossRefGoogle Scholar
  62. 62.
    Chamberlain MC, Kormanik P: Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 1998, 55:506–512.PubMedCrossRefGoogle Scholar
  63. 63.
    Siegal T: Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol 1998, 38:151–157.PubMedCrossRefGoogle Scholar
  64. 64.
    Giannone L, Greco FA, Hainsworth JD: Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 1986, 4:68–73.PubMedGoogle Scholar
  65. 65.
    Hitchins RN, Bell DR, Woods RL, et al.: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987, 5:1655–1662.PubMedGoogle Scholar
  66. 66.
    Grossman SA, Finkelstein DM, Ruckdeschel JC, et al.: Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 1993, 11:561–569.PubMedGoogle Scholar
  67. 67.
    Glantz MJ, Jaeckle KA, Chamberlain MC, et al.: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999, 5:3394–3402.PubMedGoogle Scholar
  68. 68.
    Glantz MJ, LaFollette S, Jaeckle KA, et al.: Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999, 17:3110–3116.PubMedGoogle Scholar
  69. 69.
    Jaeckle KA, Batchelor T, O’Day SJ, et al.: An open trial of sustained-release cytarabine (Depocyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 2002, 57:231–239.PubMedCrossRefGoogle Scholar
  70. 70.
    Siegal T, Pfeffer MR, Steiner I: Antibiotic therapy for infected Ommaya reservoir systems. Neurosurgery 1988, 22(1 Pt 1):97–100.PubMedGoogle Scholar
  71. 71.
    Kerr JZ, Berg S, Blaney SM: Intrathecal chemotherapy. Crit Rev Oncol Hematol 2001, 37:227–236.PubMedCrossRefGoogle Scholar
  72. 72.
    Bleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973, 289:770–773.PubMedGoogle Scholar
  73. 73.
    Bokstein F, Lossos A, Siegal T: Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 1998, 82:1756–1763.PubMedCrossRefGoogle Scholar
  74. 74.
    Glantz MJ, Cole BF, Recht L, et al.: High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998, 16:1561–1567.PubMedGoogle Scholar
  75. 75.
    Boogerd W, Dorresteijn LD, van der Sande JJ, et al.: Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000, 55:117–119.PubMedGoogle Scholar
  76. 76.
    Blaney SM, Poplack DG: New cytotoxic drugs for intrathecal administration. J Neurooncol 1998, 38:219–223.PubMedCrossRefGoogle Scholar
  77. 77.
    Sampson JH, Archer GE, Villavicencio AT, et al.: Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res 1999, 5:1183–1188.PubMedGoogle Scholar
  78. 78.
    Herrlinger U, Weller M, Schabet M: New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol 1998, 38:233–239.PubMedCrossRefGoogle Scholar
  79. 79.
    Coakham HB, Kemshead JT: Treatment of neoplastic meningitis by targeted radiation using 131I-radiolabelled monoclonal antibodies. J Neurooncol 1998, 38:225–232.PubMedCrossRefGoogle Scholar
  80. 80.
    Vrionis FD: Gene therapy of neoplastic meningiosis. J Neurooncol 1998, 38:241–244.PubMedCrossRefGoogle Scholar
  81. 81.
    Rubenstein JI, Fridlyand J, Abrey L, et al.: Phase 1 study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007, 25:1350–1356.PubMedCrossRefGoogle Scholar
  82. 82.
    Chamberlain MC, Wei-Tao DD, Groshen S: A phase 2 trial of intra-CSF etoposide in the treatment of neoplastic meningitis. Cancer 2006, 31:2021–2027.CrossRefGoogle Scholar
  83. 83.
    Chamberlain MC: Alpha-interferon in the treatment of neoplastic meningitis. Cancer 2002, 94:2675–2680.PubMedCrossRefGoogle Scholar
  84. 84.
    Shapiro WR, Schmid M, Glantz M, Miller JJ: A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis [abstract]. J Clin Oncol 2006, 24(Suppl):1528.CrossRefGoogle Scholar
  85. 85.
    Boogerd W, van den Bent MJ, Koehler PJ, et al.: The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer 2004, 40:2726–2733.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Department of Neurology, Fred Hutchinson Cancer Research CenterUniversity of Washington Neuro-Oncology ProgramSeattleUSA

Personalised recommendations